

This notice in TED website: <https://ted.europa.eu/udl?uri=TED:NOTICE:454780-2019:TEXT:EN:HTML>

**United Kingdom-Runcorn: Vaccines
2019/S 187-454780**

Voluntary ex ante transparency notice

Supplies

Legal Basis:

Directive 2014/24/EU

Section I: Contracting authority/entity

I.1) Name and addresses

The Secretary of State for Health and Social Care acting as part of the Crown through the Department of Health and Social Care
2nd Floor, Rutland House
Runcorn
WA7 2ES
United Kingdom
Contact person: Lynne Nichols
E-mail: Lynne.Nichols@dhsc.gov.uk
NUTS code: UK

Internet address(es):

Main address: <https://dh.bravosolution.co.uk>

I.4) Type of the contracting authority

Ministry or any other national or federal authority, including their regional or local subdivisions

I.5) Main activity

Health

Section II: Object

II.1) Scope of the procurement

II.1.1) Title:

Contract for Supply of Hib-Men C Vaccine
Reference number: CM/PHV/19/501

II.1.2) Main CPV code

33651600

II.1.3) Type of contract

Supplies

II.1.4) Short description:

Contract for the supply of haemophilus influenza type b, meningococcal C vaccine (Hib/Men C).

II.1.6) Information about lots

This contract is divided into lots: no

II.1.7) Total value of the procurement (excluding VAT)

Value excluding VAT: 1.00 GBP

II.2) **Description**

II.2.1) **Title:**

II.2.2) **Additional CPV code(s)**

II.2.3) **Place of performance**

NUTS code: UK

Main site or place of performance:

Bedford, UK.

II.2.4) **Description of the procurement:**

The provision of a vaccine to protect against Haemophilus influenzae type b (Hib) and meningitis C (MenC), to be used in the national childhood immunisation programme.

The contracting authority estimates their requirement over the period of the contract to be up to 3 000 000 doses.

Deliveries will be required over a period of 2 years.

II.2.5) **Award criteria**

Quality criterion - Name: Available on request / Weighting: Not applicable

Cost criterion - Name: Available on request / Weighting: Not applicable

II.2.11) **Information about options**

Options: no

II.2.13) **Information about European Union funds**

The procurement is related to a project and/or programme financed by European Union funds: no

II.2.14) **Additional information**

Value — this information is considered by the supplier to be commercially sensitive information. The authority is not publishing the value so as not to prejudice the legitimate commercial interests of the supplier.

Section IV: Procedure

IV.1) **Description**

IV.1.1) **Type of procedure**

Negotiated procedure without prior publication

- The products involved are manufactured purely for the purpose of research, experiment, study or development under the conditions stated in the directive
- The works, supplies or services can be provided only by a particular economic operator for the following reason:
 - absence of competition for technical reasons

Explanation:

There is only one supplier with an exclusive global licence to manufacture and distribute this vaccine which is licensed and approved for use in the UK and due to the functions of the vaccine, there is no reasonable alternative or substitute, therefore using the negotiated procedure without prior publication is justified under Regulation 32(2)(b)(ii) and (iii) of the Public Contracts Regulations 2015.

IV.1.3) **Information about framework agreement**

IV.1.8) **Information about the Government Procurement Agreement (GPA)**

The procurement is covered by the Government Procurement Agreement: yes

IV.2) **Administrative information**

IV.2.1) **Previous publication concerning this procedure**

Section V: Award of contract/concession

V.2) **Award of contract/concession**

V.2.1) **Date of contract award decision:**

25/09/2019

V.2.2) **Information about tenders**

The contract has been awarded to a group of economic operators: no

V.2.3) **Name and address of the contractor/concessionaire**

GlaxoSmithkline UK Ltd

Brentford

United Kingdom

NUTS code: UKI75

The contractor/concessionaire will be an SME: no

V.2.4) **Information on value of the contract/lot/concession (excluding VAT)**

Total value of the contract/lot/concession: 1.00 GBP

V.2.5) **Information about subcontracting**

The contract/lot/concession is likely to be subcontracted

Section VI: Complementary information

VI.3) **Additional information:**

The contract(s) is for the benefit of the contracting authority and NHS bodies along with any other non-NHS bodies which are necessary for the delivery of services or goods to NHS bodies, local authorities, other government departments or non-departmental public bodies charged with the delivery of healthcare or health related services in the United Kingdom, Crown Dependencies and British Overseas Territories including, without limitation, the National Assembly for Wales, the Northern Ireland Assembly, and Scottish Ministers. The resulting products delivered against the contract(s) may be made available to the UK devolved administrations, Crown Dependencies and British Overseas Territories to undertake their respective vaccination programmes

VI.4) **Procedures for review**

VI.4.1) **Review body**

The High Court

Strand

London

WC2A 2LL

United Kingdom

VI.4.2) **Body responsible for mediation procedures**

VI.4.3) **Review procedure**

VI.4.4) **Service from which information about the review procedure may be obtained**

VI.5) **Date of dispatch of this notice:**

25/09/2019